RT Journal Article
T1 Efficacy of Paracetamol in Closure of Ductus Arteriosus in Infants under 32 Weeks of Gestation.
A1 Tofe, Ines
A1 Ruiz-González, Maria Dolores
A1 Cañete, Maria Dolores
A1 Pino, Asuncion
A1 Rueda, Rosa Lorena
A1 Parraga, Maria Jose
A1 Perez-Navero, Juan Luis
K1 ibuprofen
K1 paracetamol
K1 patent ductus arteriosus
K1 preterm
K1 treatment
AB Standard medical treatment for patent ductus arteriosus (PDA) closure has been indomethacin/ibuprofen or surgical ligation. Up to date, new strategies have been reported with paracetamol. The aim of this study was to present our experience with intravenous paracetamol for closing PDA in preterm neonates presenting contraindication to ibuprofen or ibuprofen had failed and no candidates for surgical ligation because of huge instability. We conducted a retrospective case series study in a neonatal intensive care unit from a tertiary hospital. 9 preterm infants ≤32 weeks of gestational age with hemodynamically significant PDA (hsPDA) were enrolled. They received 15 mg/kg/6h intravenous paracetamol for ductal closure. Demographic data and transaminase levels before and after treatment were collected. 30 preterm babies were diagnosed of hsPDA. 11/30 received ibuprofen with closure in 81.1%. 9 received intravenous paracetamol mainly due to bleeding disorders or thrombocytopenia. Successful closure on paracetamol was achieved in seven of nine babies (77.7%). There was a significant increase in transaminase levels in two patients. They required no treatment for normalization. Paracetamol is an effective option in closure PDA. It should be a first-line therapeutic option when there are contraindications for ibuprofen treatment. Transaminases must be checked during treatment.
SN 2296-2360
YR 2018
FD 2018-02-14
LK https://hdl.handle.net/10668/27733
UL https://hdl.handle.net/10668/27733
LA en
DS RISalud
RD Apr 11, 2025